Drug Type Peptide drug conjugates |
Synonyms- |
Target |
Action antagonists |
Mechanism CCR2 antagonists(C-C chemokine receptor type 2 antagonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | Preclinical | United States | 05 Nov 2025 |





